Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
C09CA08	OLMETEC	B	Olmesartan medoxomil - 20mg	20mg	Tablet, film coated	888,280 L.L
C09CA08	OLMENOR	G	Olmesartan medoxomil - 20mg	20mg	Tablet, film coated	667,890 L.L
N05AH03	OLANZAMED	G	Olanzapine - 20mg	20mg	Tablet	3,941,938 L.L
B02BD02	OCTANATE	BioHuman	Coagulation Factor VIII - 250IU	250IU	Injectable lyophilised powder for solution+diluent	13,247,110 L.L
G03GA08	OVITRELLE	BioHuman	Choriogonadotropin Alfa - 250mcg/0.5ml	250mcg/0.5ml	Injectable solution	4,145,754 L.L
H05AA02	OSTEOFORTIL	BioTech	Teriparatide - 250mcg/ml	250mcg/ml	Injectable solution	16,963,499 L.L
J01CA04	OSPAMOX	G	Amoxicillin (trihydrate) - 250mg/5ml	250mg/5ml	Powder for suspension	223,078 L.L
J01DD15	OMNICEF	B	Cefdinir - 250mg/5ml	250mg/5ml	Powder for suspension	3,670,034 L.L
C09AA01	ORBACE	G	Captopril - 25mg	25mg	Tablet	522,179 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 2mcg/ml	2mcg/ml	Injectable solution	2,218,684 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 2mcg/ml	2mcg/ml	Injectable solution	4,219,665 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 2mcg/ml	2mcg/ml	Drops solution	1,343,843 L.L
L04AA37	OLUMIANT	B	Baricitinib - 2mg	2mg	Tablet, film coated	68,053,864 L.L
A10BB12	ORBIDE	G	Glimepiride - 2mg	2mg	Tablet	209,895 L.L
J01DD15	OMNICEF	B	Cefdinir - 300mg	300mg	Capsule	2,238,842 L.L
J01DD15	OMNICEF 300	B	Cefdinir - 300mg	300mg	Capsule	2,238,842 L.L
L04AA36	OCREVUS	BioTech	Ocrelizumab - 300mg/10ml	300mg/10ml	Injectable concentrate for solution	547,517,314 L.L
L04AA36	OCREVUS	BioTech	Ocrelizumab - 300mg/10ml	300mg/10ml	Injectable concentrate for solution	L.L
L04AA32	OTEZLA	B	Apremilast - 30mg	30mg	Tablet, film coated	49,829,454 L.L
M05BA07	OSTERAL	G	Risedronate sodium - 35mg	35mg	Tablet, film coated	511,940 L.L
A10BB12	ORBIDE	G	Glimepiride - 3mg	3mg	Tablet	351,959 L.L
S01AE01	OPTIFLOX	G	Ofloxacin - 3mg/ml	3mg/ml	Drops suspension	143,791 L.L
S02AA16	OFLOMED	G	Ofloxacin - 3mg/ml	3mg/ml	Drops solution	317,403 L.L
J01XA05	ORBACTIV	B	Oritavancin (diphosphate) - 400mg	400mg	Injectable powder for concentrate for solution + solvent	157,078,205 L.L
A02BC01	OMEPRAL	G	Omeprazole - 40mg	40mg	Capsule, delayed release	499,142 L.L
A02BC01	OMEPRAZOLE ARROW	G	Omeprazole - 40mg	40mg	Injectable powder for solution	454,219 L.L
A02BC01	OMEPRAZOLE VIANEX	G	Omeprazole (sodium) - 40mg	40mg	Injectable powder for solution+diluent	467,657 L.L
A02BC01	OMEPRAZOLE-ORBUCELL	G	Omeprazole (sodium) - 40mg	40mg	Injectable solution	3,839,550 L.L
C10AA05	ORBALIP	G	Atorvastatin (calcium) - 40mg	40mg	Tablet	1,405,275 L.L
C10AA05	ORVASTA	G	Atorvastatin - 40mg	40mg	Tablet, film coated	1,170,487 L.L